β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Completed · Phase 3

Conditions studied: Acute Gouty Arthritis Flares

In brief

This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.

Key facts

Study ID

NCT01470989

Run by

Novartis Pharmaceuticals

People needed

136

Starts

2011-11-01

Expected to finish

2013-05-01

Last updated by the study team

2021-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2
• Patients treated with canakinumab in the core studies or subsequent extensions

You may not qualify if…

• Pregnant or nursing (lactating) women

Where it is running

• Novartis Investigative Site — Mobile, Alabama, United States
• Novartis Investigative Site — Norwalk, California, United States
• Novartis Investigative Site — Pasadena, California, United States
• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — Tustin, California, United States
• Novartis Investigative Site — Clearwater, Florida, United States
• Novartis Investigative Site — Jupiter, Florida, United States
• Novartis Investigative Site — Decatur, Georgia, United States
• Novartis Investigative Site — Overland Park, Kansas, United States
• Novartis Investigative Site — Topeka, Kansas, United States
• Novartis Investigative Site — Wichita, Kansas, United States
• Novartis Investigative Site — Metairie, Louisiana, United States
• Novartis Investigative Site — Opelousas, Louisiana, United States
• Novartis Investigative Site — Flint, Michigan, United States
• Novartis Investigative Site — Troy, Michigan, United States
• Novartis Investigative Site — Jackson, Mississippi, United States
• Novartis Investigative Site — Jackson, Mississippi, United States
• Novartis Investigative Site — Missoula, Montana, United States
• Novartis Investigative Site — Omaha, Nebraska, United States
• Novartis Investigative Site — Freehold, New Jersey, United States
• Novartis Investigative Site — Hickory, North Carolina, United States
• Novartis Investigative Site — Dayton, Ohio, United States
• Novartis Investigative Site — Willoughby Hills, Ohio, United States
• Novartis Investigative Site — Charleston, South Carolina, United States
• Novartis Investigative Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.